VVitenta
Medicines · Safety9 November 2026·Verified source: FDA, EMA

Your eyes: a rare sign worth knowing

MounjaroOzempicWegovy

What changed

The US Food and Drug Administration (FDA) now requires all medicines in the GLP-1 class to mention a rare condition of the optic nerve, called NAION, in their prescribing information. In the FDA's analysis of 126 clinical trials, there were 6.4 cases per 100,000 people treated for a year, compared with 3.8 in the comparison groups.

What it means for you

  1. 1The sign to watch for: a sudden, painless loss of vision in one eye, sometimes noticed on waking. If it happens, see a doctor or an eye specialist the same day.
  2. 2The condition is rare. Do not stop treatment on your own; any change is decided with your doctor.

What does not change

In the European Union, the leaflets for semaglutide medicines (Ozempic, Wegovy) have listed NAION as a very rare side effect since 2025. The FDA decision applies to the US prescribing information.

Sources

Read more

QuestionWhen should I call my doctor about side effects on Mounjaro?What the official leaflet says and what people who went through it did.Read →

Is something missing on Vitenta?

Tell us what to add or what wasn't clear. Anonymous — no name, e-mail or phone.

What you write reaches only the team and is never shown on the site. Any content change is checked against the official leaflet.

Your suggestion
0/500 characters

Please don't include personal details.